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Abstract
Background: Bovine leukemia virus (BLV) infection is widespread in cattle globally and is present in marketed beef
and dairy products. Human infection with BLV has been reported in breast and lung cancer tissues and was
significantly associated with breast cancer in 3 case-control studies. The purpose of this current research was to
determine if BLV is present in human blood cells and if antibodies to BLV are related to blood cell infection.
Methods: Standard liquid PCR and Sanger DNA sequencing were used to test for BLV in buffy coat cells
(leukocytes and platelets) of blood specimens from 95 self-selected female subjects.
Enzyme-linked immunosorbent assay (ELISA) for IgG, IgM, and IgA was used to detect antibodies to BLV in the
plasma of the corresponding blood samples.
Results: BLV DNA was detected in the buffy coat cells of blood in 33/95 (38%) of the subjects by PCR and DNA
sequencing. IgG antibodies were detected in 30/95(32%), IgM in 55/95(58%), and IgA in 30/95(32%) of the subjects.
There was no significant correlation between presence of the antibodies and presence of BLV DNA.
Conclusions: This first report of BLV in human blood raises the question of whether infection of leukocytes could
conceivably lead to leukemia as it does in infected cattle. Also, system wide circulation of infected blood cells could
facilitate BLV transit to various internal tissues/organs with potential for their infection and subsequent
development of cancer. The most likely route of BLV transmission to humans would be zoonotic, as a foodborne
infection. Although eradicated from cattle in some countries, BLV still has a high rate of infection in the Americas,
the Middle East, and parts of Europe and Asia. This report of BLV in the blood layer containing human leukocytes/
platelets adds important information which could be useful to elucidate possible routes of transmission of BLV to
humans and to prevent further human infection.
Keywords: Bovine leukemia virus, Human blood, Zoonotic infection
Background
Bovine leukemia virus (BLV) is an oncogenic deltaretro-
virus that is emerging as a possible zoonotic infection.
BLV is widespread globally in domesticated cattle,
especially in the Americas, and parts of Europe, Asia
and the Middle East. In the USA, 84% of US dairy herds
and 39% of beef herds are infected [1]. Only 5% of in-
fected animals develop leukemia or lymphoma, requiring
exclusion of their products from the agricultural market.
The remaining 95% of the infected animals remain
subclinical with persistent lymphocytosis, and are a
major source of beef and dairy products [2, 3]. In cattle
BLV is found primarily in blood lymphocytes (B cells),
endothelial cells [2], and in mammary epithelial cells
(MEC), which frequently exfoliate into milk [4].
BLV infects a few species naturally, especially if they
are near cattle: water buffalo, sheep, alpaca [5, 6]. It has
been experimentally transmitted to rabbits, rats, pigs,
goats, and sheep [5]. Evidence that BLV infects humans
has been accumulating over the past 5 years. Although
BLV is classified as an RNA virus (deltaretrovirus
family), upon entry into a cell, it rapidly makes a DNA
copy of its genome with its reverse transcriptase enzyme,
and this retrotranscribed DNA is what predominates in
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infected cells [5]. Retrotranscribed BLV DNA has been
independently identified in the breast tissue (both
benign and malignant) of human females in Columbia
[7], the USA [8, 9], Australia [10], and Argentina [11] in
5 separate investigations using standard liquid PCR and/
or in situ PCR. These studies obtained slightly different
frequencies of women whose breast tissues were positive
for BLV, which would be expected because the propor-
tions of women with breast cancer vs. normal controls
were different and the populations were from different
countries with distinct variations in ethnicity and dietary
preferences: Columbia = 43/105 (41%) [7]; Australia =
59/96 (61%) [10]; Argentina = 12/25(48%) [11]; and two
different regions of the USA: East and Southeast = 97/
218 (44%) [8], and Texas = 73/214 (34%) [9]. BLV was
also detected in 8/10 [80%] human squamous cell lung
carcinomas by a sequence based methodology using a
microbial detection microarray that detects all viral and
bacterial families whose genomes have been sequenced
[12]. This microarray method is estimated to have a sen-
sitivity somewhat less than standard PCR but more than
next generation sequencing (NGS), which detects only
viral DNA integrated into the human genome, often
present in concentrations too low (< 1% of the reads) to
be detected without amplification [13].
These previous studies identifying BLV in human tis-
sues emphasize the need to determine how BLV infects
humans. Based on the predominance of BLV in blood
leukocytes of infected cattle and its common transmis-
sion to other cattle via blood, the goal of this study was
to determine if BLV is present in human blood leuko-
cytes, an essential first step to determine the route of
transmission of BLV to humans and how the initial
infection might spread to secondary sites.
Methods
Study population
The study population was a self-selected convenience
population of 95 female patients at Kaiser Permanente
Hospital, San Rafael, CA, responding to recruitment
flyers posted in patient waiting rooms. Participating vol-
unteers signed informed consent agreements to have an
extra tube of blood drawn for the study during the rou-
tine pre-operative blood draw the day before scheduled
surgeries of various types. Use of human subjects was
approved by Kaiser Permanente Northern California
Institutional Review Board and the University of
California, Berkeley (UCB) Committee for the Protection
of Human Subjects.
Blood processing
Blood specimens were obtained from the clinical labora-
tory where the blood had been drawn into a tube
containing an anti-coagulant and refrigerated at 4 °C.
After transfer of specimens to the research laboratory at
UCB 2–14 days later, blood was centrifuged (500×g for
10 min). Degree of hemolysis (erythrocyte rupture) in
the plasma was subjectively judged as a possible indica-
tor of blood specimen deterioration, and recorded as no
hemolysis (normal pale yellow color of plasma), slight
hemolysis (slightly pink color), or moderate hemolysis
(pale red color). No samples were completely hemolyzed
and only 2 out of 95 were moderately hemolyzed. After
removal of plasma, the intact visible leukocyte and
platelet-rich buffy coat above the red blood cells was
transferred to a separate tube. Both plasma and buffy
coat specimens were frozen at − 20 °C. until they were
used for analysis.
DNA extraction
DNA was extracted from the blood buffy coat layer using
the QIAamp® DNA mini kit (Qiagen, Valencia, CA, USA,
catalogue #51304) according to manufacturer’s instruc-
tion. The positive control cell line was FLK, a sheep cell
line derived from fetal lamb kidney and infected with BLV
[14]. FLK monolayers were detached from their substrate
by standard saline-trypsin-versene (STV) solution, rinsed
with Dulbecco’s modified phosphate buffered saline
(DPBS) and pelleted (500×g) before DNA extraction. The
negative control for PCR was sterile, filtered distilled water
added to the reaction mix in the same volume as the sam-
ples added to the reaction mix. The quality of extracted
DNA from each human blood specimen was confirmed
by electrophoreses (100 V for 30 min) on a 1.5%
agarose gel in Tris, boric acid, EDTA (TBE) buffer to
detect an ethidium bromide stained amplified segment
of the gene for the human housekeeping enzyme,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
A strong compact band at the correct position on the
gel indicated high quality DNA suitable and in suffi-
cient amount for PCR and sequencing.
PCR
For amplification of BLV that might be present in the
sample, Taq polymerase (Promega GoTaq® Flexi DNA
Polymerase, catalogue #M8296) was used in a standard
liquid PCR procedure. PCR primers and cycling condi-
tions for GAPDH are as follows:
3′-5′ GAGTCAACGGATTTGGTCGT
5′-3′ TTGATTTTGGAGGGATCTCG
using cycling condition as follows: 36 cycles: 95 °C – 2
min; 95 °C – 30 s, 50 °C – 30 s, 72 °C – 22 s; 1 cycle 72 °C
– 5 min.
All specimens positive for BLV were checked for a
sheep housekeeping gene to rule out contamination
from the positive control cell line, derived from a lamb’s
kidney. PCR primers and cycling conditions for sheep
cytochrome C oxidase are as follows [15]:
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3′-5′ CGATACACGGGCTTACTTCACG
5′-3′ AAATACAGCTCCTATTGATAAT
using cycling condition as follows: 35 cycles: 95 °C – 2
min; 95 °C – 30 s, 53 °C – 30 s, 72 °C – 24 s; 1 cycle 72 °C
– 5 min.
Standard liquid PCR using nested primers was used to
detect BLV in DNA extracted from buffy coat cells. The
BLV primers used were from the long terminal repeat
(LTR) promoter region, the gag region coding for the p24
capsid protein, the env region coding for the gp51 enve-
lope protein, and the tax region coding for the oncogenic
protein. Each genome region was tested individually be-
cause the individual pairs of primers required different re-
action conditions. Table 1 presents the primer specifics.
DNA sequencing
Amplified DNA sequences were purified using Zymo-
clean™ Gel DNA Recovery Kit (Zymo Research, Irvine,
CA, Catalogue # D4007) before sending a 25-100 ng
sample (depending on sequence length) to the UCB
DNA Sequencing Facility for Sanger sequencing. Se-
quences were run in both forward and verse directions
and checked against corresponding electropherograms.
They were accepted as readable only if they matched in
both directions and each base was clearly identifiable,
i.e. no “N’s” were indicated in the sequences.
Precautions to prevent DNA cross contamination
Throughout all laboratory work with initial specimens
and DNA, special precautions were used to prevent
cross contamination among individual specimens and
the positive control: separate rooms/work units
dedicated to a particular step of the procedure, e.g.
DNA-free room to prepare PCR reaction mix; special
hood with UV light and nucleic acid decontamination
solutions (RNAse AWAY, Molecular Bioproducts, San
Diego, CA, USA) for the addition of DNA to the reac-
tion mix; dedicated biohazard hood for all work with the
positive control cell line, and fume hood with external
exhaust for all work with the positive control DNA.
Enzyme-linked immunosorbent assay (ELISA) for anti-BLV
antibody detection
Indirect ELISA was used to assess three isotypes (IgG,
IgM, and IgA) of serum antibodies to BLV p24 capsid
protein. ELISA plates (Immulon 2HB, Thermo Fisher
Scientific, Waltham, MA) were coated with 1250 ng/well
recombinant BLV capsid p24 antigen (formerly sold by
Synbiotics, San Diego, CA). Antigen concentration was
1250 ng/well, diluted in 200 μl carbonate-bicarbonate
coating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH
9.6) plus 0.0002% purified BSA (bovine serum albumin).
After overnight incubation at 4 °C, coating buffer was
removed and wells were washed for 5 min with ELISA
wash buffer (DPBS with 0.055 Tween 20). Wells were
then incubated 1 h at room temperature with 1.5%
bovine serum albumin (BSA) in DPBS to block
non-specific reactions. Plates were washed with wash
buffer for 5 min after each subsequent step, except
blocking and detection steps. All reactions and wash
Table 1 Primers and reaction conditions used to detect BLV DNA in human buffy coat cells
BLV gene Primer sequences 5′ to 3′ Location in bp* Nested PCR role Product length, bp Annealing temp, °C. Extension time, s
LTR F: TAGGAGCCGCCACCGC 23–38 Outer 329 57 22
R: GCGGTGGTCTCAGCCGA 352–336
F: CGTAAACCAGACAGAGACG 41–59 Inner 290 58 20
R: CACCCTCCAAACCGTGCTTG 331–312
gag F: AACACTACGACTTGCAATCC 1068–1087 Outer 385 54 28
R:GGTTCCTTAGGACTCCGTCG 1453–1434
F: ACCCTACTCCGGCTGACCTA 1097–1116 Inner 272 56 24
R:CTTGGACGATGGTGGACCAA 1369–1350
env F:CGGGCAAAACAATCGTCGGT 4701–4720 Outer 707 55 45
R:ACTGGGTTCCCTCTGTCAGA 5408–5389
F: CTCTCCTGGCTACTGACC 4763–4780 Inner 611 55 45
R: GGAAAGTCGGGTTGAGGG 5374–5357
tax F: TATTCCACCTCGGCAC 7153–7169 Outer 447 50 28
R: ATTGGCATTGGTAGGGCT 7600–7583
F: CTTCGGGATCCATTACCTGA 7197–7216 Inner 373 55 24
R: GCTCGAAGGGGGAAAGTGAA 7570–7551
Abbreviations: bp base pair, F forward, R reverse, s seconds, temp temperature; bp* Base pair numbering is according to GenBank reference sequence EF600069
Reverse primer sequences for GAPDH and all BLV genome regions are presented in reversed order and complementary to the proviral reference sequence
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steps utilized a 200 μl volume and were performed at
room temperature. Primary antibody was the human
blood plasma specimen diluted 1:100 in wash buffer and
reacted 120 min. Secondary antibody was a biotinylated
goat anti-human antibody specific for IgG, IgM, or IgA
(Vector Laboratories Burlingame, CA) diluted 1:67 in
wash buffer and reacted for 120min. The biotin marker
on the adhering secondary antibody was detected using
VECTASTAIN ABC reagent (Vector Laboratories) and
the chromagen, 3,3′-diaminobenzidine (Sigma Aldrich, St.
Louis, MO), reconstituted according to manufacturer’s in-
structions, and reacted with test samples for 10min. After
removal of the chromagen, 100 μl distilled water was
added to each well. Optical density was measured at 492
nm in a SpectraMax M2 ELISA reader (Molecular De-
vices, Sunnyvale, CA). The plate was blanked on a well
containing only distilled water. All samples were run in
triplicate. During each assay, the following controls were
run to insure accuracy: one known positive and one
known negative for each antibody isotype, as determined
in a previous study by immunoblotting [16], the gold
standard test for antibody detection [17]. In addition, a
secondary antibody control, using wash buffer in place of
primary antibody, was used to adjust for any non-specific
binding of the secondary antibody.
Samples were classed as positive or negative based on
cutoff values determined by ROC.
(receiver operating characteristic) curves [18]. The
range of sensitivity and specificity values plotted on the
ROC y and x axes respectively, were based on samples
determined to be positive and negative in a previous
study using immunoblotting, more specific for detecting
anti-BLV antibodies in cattle serum [16]. ROC modifica-
tions correct for potentially false positive ELISA values,
reducing the number of positive samples, but increasing
the specificity of the assay.
Statistical analysis
Specimens were considered positive or negative for each
of the primary genome regions tested (LTR, tax, gag)
only if positive PCR results were obtained at least twice,
each in independent PCR assay batches. Raw data were
uploaded onto STATA 14 for analysis [19]. Prevalence of
BLV in blood was computed using base functions. Asso-
ciation of BLV presence with donor age, degree of blood
sample hemolysis, and presence of antibody isotypes
were each determined using unconditional multivariable
logistic regression [19]. Using standard statistical proce-
dures, P values were derived from Pearson chi square
tests, or Mann-Whitney U test.
Results
The number of study subjects positive for at least one of
three BLV genome regions tested was 36/95 (38%).
Frequencies varied for the three genome regions tested:
LTR = 22/95(23%), tax = 21/95 (22%), gag = 12/95(13%),
both tax and LTR = 12/95 (13%), LTR, gag, tax = 5/
95 = 5%. Comparing BLV positive versus BLV negative
samples, there was no significant difference in study sub-
ject age (P = 0.93; two-tailed Mann-Whitney U test) or
degree of blood specimen hemolysis (P = 0.828; Pearson
chi square test). Only samples positive for the LTR pro-
moter region were sequenced because the LTR is a
highly conserved BLV genome region, i.e. not deleted
out of the virus genome, and the largest number of sub-
jects were positive for this region. LTR also has the
greatest degree of sequence variation among the two
highly conserved regions (LTR and tax) [20]. The se-
quences were compared against BLV LTR sequences de-
posited in Gen Bank [21]. At least one country in each
of the 10 BLV genotype groups based on the env region
[1] was represented by at least one reference sequence
from the LTR region. All readable LTR sequences are
presented in Fig. 1. Sequences from 20/22[91%] subjects
were an exact match with the consensus sequence of the
GenBank reference sequences, including EF600696, de-
rived from the DNA of a US cow [21], and therefore likely
to represent the BLV strain that a human population in
the USA might be exposed to. Of the two LTR DNA se-
quences that did not match reference sequences, one
(KPM23), had a single base variation at base #80 (G re-
placed by A) like reference sequence DQ288175, based on
DNA isolated from a US cow from the state of Pennsylva-
nia. However, two other variations of KPM23 at bp142–3
and bp152–3 did not match sequence DQ288175 or any
other reference sequence. The other human sequence
(KPM38) had one variation at base #191 (A replaced by
G) which did not match any of the reference sequences
deposited in GenBank. The sequence of the FLK positive
control cell line is identical to reference sequence
EF600696, which was based on the FLK cell line first se-
quenced in 1985 by other investigators [22].
Two approaches were taken to confirm that BLV LTR
sequences matching the positive control cell line were
not the result of cross-contamination with DNA from
the control cell line. All BLV-positive human DNA sam-
ples were assayed for the presence of sheep cytochrome
C oxidase, a housekeeping gene unique to sheep [15],
the species from which our positive control cell line
originated. For samples positive for the env region,
additional sequencing was performed on the BLV env
region containing a signature mutation at bp 5194 (G
substituted for C), unique to our stock of the FLK cell
line and unlike any BLV sequence deposited in GenBank
[21]. None of the human BLV-positive samples exhibited
either of these markers of positive control cell line
contamination. Also, no variations from the reference
sequences were seen in the human envelope region.
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Fig. 1 (See legend on next page.)
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Presence of antibodies to the BLV (p24 capsid protein)
Frequency of subjects positive for the three antibody
isotypes assayed was as follows: IgG = 30/95(32%), IgM
= 55/95 (58%), IgA = 30/95(32%). The difference in
frequency of antibody isotypes in BLV-positive versus
BLV-negative subjects was not statistically significant.
There was also no significant relationship of BLV DNA
presence in the blood specimens to any of the three anti-
body isotypes tested in this study after adjustment for
hemolysis and donor age (Tables 2, 3, and 4, P values all
much greater than 0.05).
Discussion
The results of this study indicate the presence of retro-
transcribed bovine leukemia virus (BLV) DNA in blood
cells of 36/95(38%) subjects in a self-selected study
population. This corroborates previous reports of BLV
infection of human breast and lung, and suggests that
leukocytes and/or platelets are additional human cell
types that can become infected with BLV. It also raises
the possibility that BLV infection could initiate add-
itional type(s) of human cancer. Cells infected with BLV
and its close relative human T-cell leukemia virus
(HTLV) rarely produce infectious extracellular BLV par-
ticles and it appears that cell to cell contact is important
for viral transmission from an infected to an uninfected
cell [5]. Exosomes shed by BLV infected cells of cattle
might also facilitate cell to cell transmission of BLV
among cattle [23]. Therefore, circulating BLV-infected
leukocytes might be efficient agents for virus delivery to
diverse tissue types, especially internal organs. In cattle,
BLV causes the majority of leukemias and lymphosar-
comas [2]. Although non-lymphatic internal organs have
not been observed as sites of BLV associated cancer in
cattle, this may be because cattle are usually slaughtered
at 2–8 years old in a potential lifespan of 20–25 years.
This short life may limit the development of many types
of cancer and the opportunity to investigate whether
BLV might cause cancers of internal organs in older
cattle.
Although BLV is classified as an RNA virus (deltare-
trovirus family), upon entry into a cell it rapidly makes a
DNA copy of its genome with its reverse transcriptase
enzyme, a defining characteristic of all retroviruses. The
life cycle of BLV does not include host cell assisted pro-
duction of RNA copies of itself as complete virions for
export into the extracellular environment [23]. Also, un-
like retroviruses in other families, e.g. HIV, deltaretro-
viruses do not have their own independent means of
passing through the nuclear membrane in order to inte-
grate into the host genome. They can enter the nucleus
only during cell division when the nuclear membrane
temporarily dissolves [23]. The plentiful linear and circu-
lar retrotranscribed DNA genome copies of BLV found
within host cell cytoplasm are believed to be copies that
never entered the nucleus because host cells were not
dividing [23], as opposed to excised copies of BLV previ-
ously integrated into host cell DNA and then leaving to
enter the cytoplasm [24]. Frequent division of leukocytes
does not usually occur in adult humans unless they have
untreated leukemia. For these reasons, we targeted BLV
DNA rather than RNA as our indicator of BLV presence
within human leukocytes, and used standard PCR to
amplify this BLV genomic DNA, which is abundant in
the cytoplasm of infected cells. Also, our primary goal
was to search for current and historic markers of BLV
presence (DNA) in human subjects, rather than its
current activity (transcribed RNA).
An important strength of the study was the choice of
more than one BLV genome region as the target for BLV
detection. The LTR (long terminal repeat) promoter re-
gion of BLV, and tax, coding for the oncogenic protein,
(See figure on previous page.)
Fig. 1 Partial sequences of the long terminal repeat (LTR) promoter region of BLV based on DNA from blood cells of the 23 KPM study subjects
positive for the LTR (long terminal repeat) promoter region of BLV. These sequences are compared to 9 GenBank reference sequences [20] (top
left column) from 6 of the 10 BLV genotypes established through comparisons of the env sequences of BLV isolated from cattle [1]. No reference
sequences of the LTR region were available in GenBank from 3 of the genotype groups (7, 10,11). The reference sequence accession code,
specimen country of origin, and genotype group are as follows (genotypes in parentheses are probable, based on country of origin, but not
proven by phylogenetics): EF600696.1 and DQ288175.1 - USA, (genotype 1 or 3); HE967301.1 – Uruguay, (genotype 1); K02120.1 – Japan,
(genotype 1 or 3); FJ914764.1 – Argentina, genotype 2; AH001143.2 and AH002557.2 – Belgium, (genotype 4); M38278.1 – Russia, (genotype 4,7,
or 8); DQ288218 – Costa Rica, genotype 5; The first base of each 10 bases is directly under the first digit of the base pair (bp) number. Dots
indicate nucleotide bases identical to the consensus. Letters indicate bases differing from the consensus of the reference sequences. Figure
formatting was done with GeneDoc (https://genedoc.software.informer.com)
Table 2 Association of BLV presence in blood with odds of having an IgG antibody to BLV
Unadjusted Adjusted
All Subjects IgG+ IgG- OR (95% CI) P1 OR (95% CI) P1
BLV+ 36 (38%) 13 (14%) 23 (24%) 1.40 (0.52–3.69) 0.46 1.40 (0.58–3.38) 0.46
BLV- 59 (62%) 17 (18%) 42 (44%)
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were chosen because they are the most highly conserved
regions of BLV [20, 25], i.e. the least likely to be deleted
from the BLV genome. The gag and env regions coding
for the capsid and envelope proteins, respectively, are
the targets for the immune response in cattle and, in
BLV and its close relative HTLV (human T-cell leukemia
virus), the gag- pol (polymerase)- env segment of the
BLV genome is often deleted during the progression of
leukemias and lymphomas to advanced stages [5, 26],
presumably to escape the host’s immune response. Viral
detection could possibly be missed if these regions were
the primary or sole target for assays. Therefore, although
we tested for the gag region, we did not include the env
region for the initial screening for BLV detection, as in
cattle, it is commonly deleted [26]. For sequencing, the
LTR region was chosen because it shows greater
sequence variation (single base substitutions) than tax
[20, 25]. Base substitutions are valuable for genome
comparisons in viruses such as the deltaretroviruses, e.g.
BLV and HTLV, which have high genomic stability and a
low overall mutation rate compared to other oncogenic
retroviral families and to lentiviruses, e.g. HIV [5, 23].
Sequence variations also aid in identifying each spe-
cimen and checking for contamination from the posi-
tive control cell line and cross contamination among
different virus isolates. Neither of the two specimens
we obtained with variations from the reference se-
quences shared the same base substitution or had a
base substitution identical to the FLK positive control
cell line, as illustrated in Fig. 1, suggesting no cross
contamination among DNA specimens from different
study participants. Although the overall number of se-
quence differences among the 7625 nucleotides con-
stituting the 23 specimens sequenced is small and
within the range of sequence error for Taq polymer-
ase [27], it is unlikely that they represent Taq poly-
merase error since the FLK positive control cell line,
when sequenced in our laboratory, showed no vari-
ation from the Standard Nucleotide BLAST site BLV
reference sequence EF600696 which was based on the
FLK cell line sequenced in 1985 [22].
Another strength of this study is that the primer se-
quences were chosen because of their high homology with
BLV (E ≤ .28–.31), and low homology with other retrovi-
ruses and the human genome including endogenous ret-
roviruses (E = 2.3–750), based on the Standard Nucleotide
BLAST option [21]. The purpose of testing primer specifi-
city on the BLAST (Basic Local Alignment Search Tool)
site was to compare primer specificity for only two spe-
cies: bovine leukemia virus and Homo sapiens, and to
insure that the primers we used were detecting only
bovine leukemia virus and not other retroviruses or the
human genome, including endogenous retroviruses. Since
the BLAST nucleotide data base includes sequences for
49,985,097 different species of organisms, we followed the
advice of the BLAST instruction site and narrowed the
search in the nucleotide database to bovine leukemia virus
only (in box entitled “organism”). We also set the parame-
ters to search only for “highly similar sequences,” which
greatly reduces the number of nonspecific matches. When
the search results came up we looked only at genomes,
not “transcripts” or “protein” matches, since our study
was based strictly on DNA genome similarities. E values
are a measure of the similarity of two sequences being
compared. E values ≤1.00 indicate low probability of ran-
dom chance similarity and therefore a high specificity as a
primer match for the targeted BLV sequence; E values >
1.00 indicate a high probability that sequences being com-
pared are similar due to random chance rather than true
relatedness and therefore, as applied to the BLV primers
we used, a very low probability that our primers were
amplifying human genome sequences including endogen-
ous retroviruses. The strongest confirmation of the speci-
ficity of our primers comes from previous laboratory
testing which indicated that both the tax and LTR primers
used here amplified a BLV product, but failed to amplify a
product when tested on HTLV (human T-cell leukemia
virus) and representatives of all other retroviral and
Table 3 Association of BLV presence in blood with odds of having an IgM antibody to BLV
Unadjusted Adjusted
All Subjects IgM+ IgM- OR (95% CI) P OR (95% CI) P
BLV+ 36 (38%) 21 (22%) 15 (16%) 1.03 (0.41–2.61) 0.95 1.03 (0.44–2.38) 0.95
BLV- 59 (62%) 34 (36%) 25 (26%)
Table 4 Association of BLV presence in blood with odds of having an IgA antibody to BLV
Unadjusted Adjusted
All Subjects IgA+ IgA- OR (95% CI) P OR (95% CI) P
BLV+ 36 (38%) 14 (15%) 22 (23%) 1.71 (0.64–4.52) 0.23 1.71 (0.71–4.13) 0.23
BLV- 59 (62%) 16 (17%) 43 (45%)
1Unadjusted -P values are derived from one-sided chi-squared distribution. Adjusted p-values are derived from two-sided z-test from unconditional logistic
regression, adjusting for P age as confounding variable
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lentiviral families, human papillomavirus, Epstein-Barr
virus, and human endogenous retrovirus K [28].
Statistical strengths of the study are that the
BLV-positive and BLV-negative subjects were by chance,
quite similar in terms of age distribution, reducing the
potential for age-related confounding. Also, as internal
validations, statistical analyses were performed inde-
pendently by two persons (M.B. and D.S.), and ELISA
assays were performed independently at different times
by two persons (N.R. and D.C) in each case blinded as
to each other’s results. The two sets of ELISA values
were consistent with each other and the final conclu-
sions of the two independently conducted statistical ana-
lyses were identical.
Because the BLV DNA was assayed using extracted
DNA rather than an in situ technique, we could not ver-
ify that the virus was intracellular. However, the source
of the DNA was the concentrated buffy coat (leukocytes
and platelets) and the strong gel electrophoresis band
obtained for the human housekeeping gene GAPDH
suggests that cellular DNA was abundant in the DNA
extract. The amount of material obtained from buffy
coats of 7-8 ml. blood samples, however, was not suffi-
cient to separate leukocytes into different categories and
determine which individual cell types were infected, or
to investigate protein biomarkers of virion production.
These would be important objectives for future studies
using blood samples with greater volume. Finally, be-
cause clinical information on the self-selected donor
population consisted only of age and gender, it was
impossible to investigate the association of BLV presence
in leukocytes with any specific diseases.
Results of the antibody ELISA assays were consistent
with those of a previous study using immunoblotting
[16]. Both studies showed that humans have IgG, IgM,
and IgA antibodies to BLV. Although detection of anti-
bodies to viruses is a common and extremely useful
means of diagnosing viral diseases, in the case of BLV
infections, relying on antibodies to prove infection has
several disadvantages. BLV may not express p24 capsid
protein in blood cells and may not replicate there. Stud-
ies in cattle indicate that lymphocytes harboring BLV
provirus rarely produce extracellular virions or express
viral proteins even though the cattle have antibodies to
BLV [16]. The exact site(s) of viral expression in cows
that stimulate the production of serum antibodies
against BLV was elusive for decades [1]. However, in
1994 when cells isolated from the milk of lactating dairy
cows were tested, a high level of p24 was detected within
the mammary epithelial cells of 10/28(36%) cows [4]. In
humans, a previous study on breast tissue specimens
indicated that only 12/215 (6%) of specimens positive for
BLV by PCR showed p24 expression in mammary
epithelial cells [28]. A possible explanation for the
greater frequency of BLVp24 expression in cattle could
relate to hormones. Dairy and beef cows are kept in a
constant state of pregnancy and lactation during their
adult life, whereas most human females are not. BLV
genomic transcription is hormone responsive via a
hormone response element in the LTR region [29] that
is stimulated by progesterone and corticosteroids [30].
In the current and previous studies on BLV in humans,
most subjects were beyond the usual age range for preg-
nancy and lactation, the reproductive phases during
which human progesterone and cortisol levels are high-
est. At human parturition, maternal progesterone is 6x
higher and cortisol 70x higher than in the nonpregnant
state [31]. In this study, we were unable to determine
the association between antibody presence and repro-
ductive phase the subject may have been in at the time
blood was drawn. The limited information available on
each donor did not include history of pregnancy and
lactation, or use of corticosteroid medications.
For antibody isotypes IgG and IgA, BLV-positive
subjects were more likely to have anti-BLV antibodies
than BLV-negative subjects. However, the differences
were not statistically significant. The most probable
explanation for the presence of human antibodies to
BLV is an immune reaction to heat inactivated BLV
consumed in pasteurized dairy products and cooked beef
products. Numerous studies in cattle indicated that vac-
cination of cattle with inactivated, non-infectious BLV
resulted in production of antibodies to BLV, although
the strength of the humoral immune response was not
as great as with infectious BLV [32]. In a previous study
it was shown that human antibodies to BLV p24 protein
reacted equally well with heat inactivated (boiled) versus
unheated purified p24 antigen [16]. Most humans in the
USA drink pasteurized dairy products and cooked beef
products, which may stimulate anti-BLV antibody pro-
duction. Therefore, the presence of human antibodies to
BLV may be a less accurate indication of BLV infection
than the presence of BLV DNA in human cells.
The general assumption about BLV infection of
humans is that it is a zoonotic infection, although the
possibility of human to human transmission, presumably
through blood and/or breast milk, has not been investi-
gated. Epidemiologic observations certainly support a
zoonosis. It has been noted for decades that the coun-
tries with the highest consumption of dairy products
have the highest incidence of breast cancer [33, 34]. Red
meat consumption has also been associated with breast
cancer incidence [35].
Phylogenetic analyses are usually useful to analyze
homology among DNA nucleic acid sequences and de-
termine reservoirs of infectious agents that cause human
disease. However, for deltaretroviruses (BLV and HTLV),
this type of analysis is extremely difficult because the
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low mutation rate decreases the number of DNA se-
quence variations to compare. In the human sequences
we report here, there were only occasional single base
differences compared to GenBank BLV sequences from
cattle specimens (≤3.5% of the LTR region), suggesting
close homology with bovine BLV sequences. Other gen-
ome regions were often deleted, eliminating any possibil-
ity of sequencing them. Phylogenetic trees for different
genome regions of BLV isolated from cattle globally have
been established [1, 20, 25] and show relatively few
variations (base substitutions) among the different
geographic areas. What is needed to be conclusive about
the homology between human and bovine BLV isolates
is more sequences of human isolates for comparison, es-
pecially from globally diverse areas. This may take many
years to accumulate, especially since multiple BLV gen-
ome areas are frequently deleted and therefore whole
genome sequencing is not very efficient. This finding of
BLV in human blood leukocytes is hopefully, a first step
that will inspire other investigators to sample humans in
their own global areas, so that eventually collaborative
global sequence comparisons among human and bovine
sequences could be made and possibly contribute to
establishing the reservoir for BLV infection of humans.
Conclusions
This initial finding of BLV in human blood cells adds a
new member to the human tissue types previously found
to harbor BLV viz. breast and lung. This is relevant to hu-
man cancer because the BLV Tax protein inhibits base ex-
cision repair of the oxidative damage to cellular DNA
[36], which occurs naturally as a byproduct of normal cell
metabolism. This could explain the multiple somatic cell
mutations observed in advanced leukemia/lymphomas
caused by BLV in cattle [37] and may also explain why hu-
man breast and other cancer types have an array of som-
atic cell mutations [38] that are now being targeted by
therapeutic drugs. BLV infection and resultant microRNA
production have also been shown to have detrimental ef-
fects on the immune system of cattle [39], which might
play an important role in advancing the progression of
early carcinomas. Thus, BLV has the potential to be an
important initiator of cancer in human tissues, and the
data reported here further strengthen the evidence that
BLV infected cattle pose a likely risk to humans.
Ackowledgements We thank the following at Kaiser
Permanente Hospital, San Rafael, CA: Karen Kidd, RN
for help with specimen acquisition and medical records,
and clinical laboratory personnel for drawing blood from
study subjects. We are grateful to the following at
University of California, Berkeley: Dr. Sangwei Lu for
the use of her ELISA reader and Yvonne Hao for assist-
ance with manuscript preparation.
Abbreviations
BLAST: Basic local alignment search tool; BLV: Bovine leukemia virus; bp: Base
pair; DPBS: Dulbecco’s modified phosphate buffered saline; env: bovine
leukemia virus genome region that codes for the envelope glycoprotein 51;
FLK: Fetal lamb kidney; gag: region of the bovine leukemia virus genome
that codes for the capsid antigen; GAPDH: Glyceraldehyde-3-dehydrogenase;
HTLV: Human T-cell leukemia virus; KPM: Kaiser Permanente; KPNC: Kaiser
Permanente of Northern California; LTR: Long terminal repeat promoter
region of bovine leukemia virus; OR: Odds ratio; tax: region of the bovine
leukemia virus genome that codes for the transactivating oncogenic protein;
UCB: University of California, Berkeley
Funding
This research was supported by a grant from the National Cancer Institute
(NCI) at the National Institute of Health (NIH) to Gertrude C. Buehring
(#5R03CA117318–02, Markers of human infection with bovine leukemia virus).
Availability of data and materials
The data sets compiled and analyzed for the current study are available from
the corresponding author on reasonable request. Materials may be available
if our supply has not been expended, e.g. specimens and expensive
reagents.
Authors’ contributions
MB, AD, and GCB conceived of and designed the study. The specimen
collection was arranged and carried out by AD and GCB. The experiments
were performed by HMS, NR, and DLC. The statistical analyses were
performed by DAS and MB, and ROC analyses by ZD. All authors contributed
to the manuscript preparation and approved the final version.
Ethics approval and consent to participate
Participating volunteers signed informed consent agreements to have an
extra tube of blood drawn for the study during the routine pre-operative
blood draw the day before scheduled surgeries of various types. Use of hu-
man subjects was approved by Kaiser Permanente Northern California (KPNC)
Institutional Review Board and the University of California, Berkeley (UCB)
Committee for the Protection of Human Subjects.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1School of Public Health, University of California, 16 Barker Hall, Berkeley, CA
94720-7354, USA. 2Kaiser Permanente Medical Cente, San Rafael, CA, USA.
3Oakland University William Beaumont School of Medicine, Oakland, MI, USA.
4University of Michigan Medical School, Ann Arbor, MI 48109, USA. 5Joint
Medical Program, University of California, Berkeley, CA, USA. 6University of
California, San Francisco, CA, USA. 7RTI International, San Francisco, CA, USA.
Received: 12 October 2018 Accepted: 7 March 2019
References
1. Polat M, Takeshima S, Aida Y. Epidemiology and genetic diversity of bovine
leukemia virus. Virol J. 2017;14:209-24.
2. Nagy DW. Overview of bovine Leukosis. In: Merck veterinary manual.
Kenilworth, New Jersey: Merck Inc; 2014.
3. Olaya-Galán NN, Corredor-Figueroa AP, Guzmán-Garzón TC, Ríos-Hernandez
KS, Salas Cárdenas SP, Patarroyo MA, et al. Bovine leukaemia virus DNA in
fresh milk and raw beef for human consumption. Epidemiol Infect. 2017;
145:3125–30.
4. Buehring GC, Kramme PM, Schultz RD. Evidence for bovine leukemia virus
in mammary epithelial cells of infected cows. Lab Investig. 1994;71:359–65.
Buehring et al. BMC Infectious Diseases          (2019) 19:297 Page 9 of 10
5. Gillet NA, Florins A, Boxus M, Burteau C, Nigro A, Vandermeers F, Balon H,
Bouzar A-B, Defoiche J, Burny A, Reichert M, Kettman R, Willems L.
Mechanism of leukemogenesis induced by bovine leukemia virus: prospects
for novel anti-retroviral therapies in human. Retrovirology. 2007;4:18 doi:
1186/1742-4690-4-18.
6. Lee LC, Scarrett WK, Buehring GC, Saunders GK. Bovine leukemia virus
infection in a juvenile alpaca with multicentric lymphoma. Can Vet J.
2012;53:283–6.
7. Mesa G, Ulloa JC, Uribe AM, Gutierrez MF. Bovine leukemia virus gene
segment detected in human breast tissue. Open J Med Microbiol.
2013;03:84–90. https://doi.org/10.4236/ojmm.2013.31013.
8. Buehring GC, Shen HM, Jensen HM, Jin DL, Hudes M, Block G. Exposure to
bovine leukemia virus is associated with breast cancer: a case-control study.
PLoS One. 2015;10:1–13.
9. Baltzell KA, Shen HM, Krishnamurthy S, Sison JD, Nuovo GJ, Buehring GC.
Bovine leukemia virus linked to breast cancer but not coinfection with
human papillomavirus: case-control study of women in Texas. Cancer.
2018;124:1342–9.
10. Buehring GC, Shen H, Schwartz DA, Lawson JS. Bovine leukemia virus linked
to breast cancer in Australian women and identified before breast cancer
development. PLoS One. 2017;12:e0179367. https://doi.org/10.1371/journal.
pone.0179367.
11. Lendez P, Nieto Farias M, Buehring G, Shen H, Dolcini G, Ceriani M. Bovine
leukemia virus associated with mammary epithelial cell proliferation in
Argentinian women. In: XI Argentinian virology congress and II
Latinoamerican virology congress; 2015.
12. Robinson LA, Jaing CJ, Pierce Campbell C, Magliocco A, Xiong Y, Magliocco
G, et al. Molecular evidence of viral DNA in non-small cell lung cancer and
non-neoplastic lung. Br J Cancer. 2016;115:497–504. https://doi.org/10.1038/
bjc.2016.213.
13. Gardner SN, Jaing CJ, McLoughlin KS, Slezak TR. A microbial detection array
(MDA) for viral and bacterial detection. BMC Genomics. 2010;11.
14. Van Der Maaten MJ, Miller JM. Replication of bovine leukemia virus in
monolayer cell cultures. Bibl Haematol. 1975:360–2.
15. Cooper JK, Sykes G, King S, Cottrill K, Ivanova NV, Hanner R, Ikonomi O.
Species identification in cell culture: a two-pronged approach. In Vitro Cell
Dev Biol. 2007;43:344–51.
16. Buehring GC, Philpott SM, Choi KY. Humans have antibodies reactive with
bovine leukemia virus. AIDS Res Hum Retrovir. 2003:1105–13.
17. Shiguekawa KYM, Mineo JR, de Moura LP, Costa-Cruz JM. ELISA and Western
blotting tests in the detection of IgG antibodies to Taenia solium
metacestodes in serum samples in human neurocysticercosis. Trop Med Int
Health. 2000;5:443–9.
18. McNeil BJ, Hanley JA. Statistical approaches to the analysis of receiver
operating characteristic (ROC) curves. Med Decis Mak. 1984;4:137–50.
19. StataCorp. Stata Statistical Software: Release 14. 2015.
20. Zhao X, Jimenez C, Sentsui H, Buehring GC. Sequence polymorphisms in
the long terminal repeat of bovine leukemia virus: evidence for selection
pressures in regulatory sequences. Virus Res. 2007;124:113–24.
21. NCBI (National Center for biotechnology information, BLAST.https://blast.
ncbi.nlm.nih.gov/Blast.cgi. Accessed 15 Feb 2019.
22. Derse D, Diniak AJ, Casey JW, Deininger PL. Nucleotide sequence and
structure of integrated bovine leukemia virus long terminal repeats.
Virology. 1985;141:162–6.
23. Goff SP, Retroviridae: The Retroviruses and Their Replication. Field's Virology,
eds. Knipe DM, Howley PM, Philadephia, Wolters Kluwer Health/Lippincott
Williams and Wilkins, 2007, Chapter 55.
24. van der Kuyl A. HIV infection and HERV expression: a review. Retrovirology. 9:6–
2012;9:6; http://www.retrovirology.com/content/9/1/. Accessed 15 Feb 2019.
25. Zhao X, McGirr KM, Buehring GC. Potential evolutionary influences on
overlapping reading frames in the bovine leukemia virus pXBL region.
Genomics. 2007;89:502–11.
26. Zhao X, Buehring GC. Natural genetic variations in bovine leukemia virus envelope
gene: possible effects of selection and escape. Virology. 2007;366:150–65.
27. Tindall KR, Kunkel TA. Fidelity of DNA synthesis by the Thermus aquaticus
DNA polymerase. Biochemistry. 1988;27:6008–13.
28. Buehring GC, Shen HM, Jensen HM, Yeon Choi K, Sun D, Nuovo G. Bovine
leukemia virus DNA in human breast tissue. Emerg Infect Dis. 2014;20.
29. Xiao J, Buehring GC. In vivo protein binding and functional analysis of cis-
acting elements in the U3 region of the bovine leukemia virus long
terminal repeat. J Virol. 1998;72:5994–6003.
30. Niermann GL, Buehring GC. Bovine leukemia virus is hormone responsive
via the long terminal repeat. Virology. 1997;239:249–58.
31. Pepe G, Albrecht ED, Steroid endocrinology of pregnancy, Glob. Libr.
Women’s med., ISSN: 1756–2228) 2008; https://doi.org/10.3843/GLOWM.
10311
32. Gutiérrez G, Rodrigues SM, de Brogniez A, Gillet N, Golime R, Burny A,
Jaworski J-P, Alvarez I, Vagnoni L, Trono K, Willems L. Vaccination against
∂-retroviruses: the bovine leukemia virus paradigm. Viruses. 2014;6:2416–27
doi:3390/v6062416.
33. Khazaei S, Rezaeian S, Khazaei Z, Molaeipoor L, Nematollahi S, Lak P, Khazaei
S. National Breast Cancer Mortality and incidence rates according to the
human development index: an ecological study. Advances in Breast Cancer
Research. 2016(5):Article ID:63093. https://doi.org/10.4236/abcr.2016.51003.
34. Charts bin, current worldwide total milk consumption per capita. chartsbin.
com/view/1491
35. Lipi G, Mattiuzzi C, Cervellin G. Meat consumption and cancer risk: a critical
review of published meta-analyses. Crit Rev Oncol Hematol. 2016;97:1–14.
https://doi.org/10.1016/j.critrevonc.2015.11.008.
36. Philpott SM, Buehring GC. Defective DNA repair in cells with human T-cell.
J Natl Cancer Inst. 1999;91:933–42.
37. Safari R, Hamaidia M, de Brogniez A, Gillet N, Willems L. Cis-drivers and
trans-drivers of bovine leukemia virus oncogenesis. Curr Opin Virol.
2017;26:15–9.
38. Nakagawa H, Fujita M. Whole genome sequencing analysis for cancer
genomics and precision medicine. Cancer Sci. 2018;109:513–22.
https://doi.org/10.1111/cas.13505.
39. Frie MC, Droscha CJ, Greenlick AE, Coussens PM. MicroRNAs encoded by
bovine leukemia virus (BLV) are associated with reduced expression of B cell
transcriptional regulators in dairy cattle naturally infected with BLV.
Front Vet Sci. 2018:1–16. https://doi.org/10.3389/fvets.2017.00245.
Buehring et al. BMC Infectious Diseases          (2019) 19:297 Page 10 of 10
